Randomized Phase II Trial of First-Line Treatment With Tailored Irinotecan and S-1 Therapy Versus S-1 Monotherapy for Advanced or Recurrent Gastric Carcinoma (JFMC31-0301)
Anti-Cancer Drugs - United States
doi 10.1097/cad.0b013e328345b509
Full Text
Open PDFAbstract
Available in full text
Date
July 1, 2011
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)